50.48 0.00 (0.00%)
After hours: 4:35PM EDT
|Bid||38.25 x 900|
|Ask||54.40 x 900|
|Day's range||47.94 - 52.16|
|52-week range||36.20 - 82.49|
|Beta (5Y monthly)||1.10|
|PE ratio (TTM)||N/A|
|Earnings date||01 Mar 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||85.81|
uniQure (QURE) delivered earnings and revenue surprises of -24.36% and 49.32%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
If you own shares in uniQure N.V. (NASDAQ:QURE) then it's worth thinking about how it contributes to the volatility of...
UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many...
BioMarin (BMRN) submits a BLA in the United States for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
uniQure (QURE) delivered earnings and revenue surprises of 30.12% and -53.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
It might be of some concern to shareholders to see the uniQure N.V. (NASDAQ:QURE) share price down 22% in the last...
uniQure (QURE) delivered earnings and revenue surprises of -10.67% and 61.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.
A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.